Drug

Androgens

In clinical development

Emerging researchLate-stage developmentRising momentum

Also known as Androgen receptor agonist, Androgen.

RxNorm777

Research papers

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Neurology of Androgens and Androgenic Supplements.

Research2025-06-03Current neurology and neuroscience reports

Society for Endocrinology Clinical Practice Guideline for the Evaluation of Androgen Excess in Women.

Research2025-05-13Clinical endocrinology

Hormone Regulation in Testicular Development and Function.

Research2024-05-26International journal of molecular sciences

RISING STARS: Androgens and immune cell function.

Research2024-04-29The Journal of endocrinology

Sexual dimorphism in skin immunity is mediated by an androgen-ILC2-dendritic cell axis.

Research2024-04-12Science (New York, N.Y.)

Sex differences in colorectal cancer: with a focus on sex hormone-gut microbiome axis.

Research2024-03-07Cell communication and signaling : CCS

Hypothalamic-Ovarian axis and Adiposity Relationship in Polycystic Ovary Syndrome: Physiopathology and Therapeutic Options for the Management of Metabolic and Inflammatory Aspects.

Research2024-01-03Current obesity reports

Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.

Research2024-01-02Nature communications

Targeting the Androgen Signaling Axis in Prostate Cancer.

Research2023-07-10Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.

Research2020-02-05Molecular metabolism

A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride

Clinical trial2019-07-01Primary completion · ClinicalTrials.gov

The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome

Clinical trial2012-06-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Androgens

Aliases & brands

Androgen receptor agonistAndrogen

RxNorm CUI

777

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2012

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 2

Phase 31Phase N / A1

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome

CompletedPH IIIThomas Jefferson Universityn=2002012

Recent completions

Trials that read out recently, adding to the completed evidence base.

The Effects of Androgen, Estrogen, and the Combination of Androgen and Estrogen on Growth Rate and Cognitive Function of Growth Hormone-treated Girls With Turner Syndrome

CompletedPH IIIThomas Jefferson Universityn=2002012

Research activity

15 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

19992025

Most influential

Gene ontology analysis for RNA-seq: accounting for selection bias.

Genome biology · 2010 · 4,928 cites

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

The Journal of clinical endocrinology and metabolism · 2006 · 1,132 cites

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Cancer research · 2008 · 1,040 cites

The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Endocrine reviews · 2016 · 938 cites

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal.

The Journal of clinical investigation · 1999 · 813 cites

Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies.

Molecular metabolism · 2020 · 300 cites

Related diseases

6 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Hyperandrogenism5 Polycystic Ovary Syndrome5 Insulin Resistance3 Prostatic Neoplasms3 Obesity2 Prostatic Neoplasms, Castration-Resistant2

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Testosterone

Studied across 9 of the same disease areas as Androgens in the shared literature.

9 shared diseases3 shared papers

Follicle Stimulating Hormone

Studied across 5 of the same disease areas as Androgens in the shared literature.

5 shared diseases1 shared paper

Tetracycline

Studied across 3 of the same disease areas as Androgens in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
Europe PMC — research literature
ClinicalTrials.gov — clinical trials